Cannabics Pharmaceuticals, Inc. (CNBX)

downloadCannabics Pharmaceuticals, Inc. is a U.S.-based company focusing on the development of and commercialization of sophisticated, advanced medicines, food supplements, therapies, and administration routes based on cannabinoids, the active ingredients and naturally occurring compounds found in unique, diverse strains of the cannabis plant.

Through the Cannabic’s research and development extension laboratory located in Israel, the company is developing a pipeline of advanced therapies based on cannabinoids. Cannabics was founded in 2012 by a group of experienced researchers from the molecular biology, pharmacology, and cancer research fields. The company, through collaboration with key medical centers in the U.S., Europe, and Israel, is now launching clinical studies that investigate the beneficial effects of the company’s products in different medical indications.

The flagship product of Cannabics Pharmaceuticals, Inc. is Cannabics SR, a proprietary sustained release capsule containing medical cannabis. Cannabics SR is specially developed as a palliative care treatment for cancer patients. The medicine provides 10 to 12 hours of therapeutic effects on patients, allowing for once-a-day oral medical cannabis dosing regimen.

The Cannabics SR capsule contains pure concentrate of cannabinoids, which are extracted from selected strains of cannabis. The substances used in the sustained release formulation are certified food-grade, and the capsule is free of chemical substances or artificial additives.

Cannabics Pharmaceuticals, Inc. is an emerging company traded in the OTC markets under the stock symbol CNBX. The company develops their proprietary technologies in certified laboratories, and they license the utilization of such technologies to both manufacturers and distributors that have adequate licenses in their local territories.

Cannabics Pharmaceuticals, Inc. is not engaged in the manufacture, distribution, dispensing, or possession of any cannabis, cannabis-based preparations, and any other controlled substances. The company’s leaders are Dr. Zohar Koren, CEO and co-founder, and Dr. Eyal Ballan, CTO and co-founder.

Cannabics Pharmaceuticals, Inc.

#3 Bethesda Metro Center, Suite #700
Bethesda, MD 20814

Phone: (877) 424-2429

Yahoo! Finance: CNBX News

Latest Financial News for CNBX

7 Marijuana Penny Stocks That I May Buy

If you invest in marijuana penny stocks, you are probably aware that over the past year many of the companies in this risky sector of the equity markets have seen significant declines in their share prices.Many of these little companies had stocks that were trading for $2 or $3 a share or even more during the ball of last year. This was due to expectations and excitement leading up to Canadian legalization. Since then, the share prices of most of these companies have fallen to just a few pennies. Once this happens, it is basically over. Very few of them will survive.The following seven companies seem to have weathered the storm over the past year. This could be an indication that they may have favorable prospects for the future. If they survive the bad times maybe they will prosper in the good times. Because of this, they are on my radar screen as potential buys.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Retail Stocks to Buy for the Second Half of 2019 Please understand that these are not recommendations. It is just a starting point for my analysis. I will be doing some more research into these companies before potentially may be making investments in them. Marijuana Penny Stocks: 48North Cannabis Corp (NRTH)48North Cannabis Corp (CVE:NRTH) produces and sells medical cannabis. It focuses on the female health and wellness market. This company is on the list because of the huge increases of trading volume that have occurred. In a situation like this, increasing volume could be a bullish signal.This is an important dynamic to understand. Stocks do not need volume to head lower, but they do need meaningful volume to go higher. This is because investors do not need to buy, but they may need to sell.For example, consider a fictional stock with every shareholder content with their positions. Buyers will not buy more, and sellers will not want to sell any.However, now suppose that one of these holders needs to raise money for an unforeseen emergency. They will be forced to sell. Because at current levels there is no buy interest, the stock will inevitably go lower because they will be forced to sell at lower prices.This increasing interest could be due to some recent news. NRTH stock's Good:House farm expects its first outdoor harvest in August, and is converting another location from cultivation to propagation, processing and packaging. This is important because outdoor marijuana is significantly cheaper to grow than greenhouse marijuana.Most marijuana is grown indoors because it is considered more secure and of better quality. But due to the huge cost advantage, investors are starting to consider outdoor growing. Two Rivers Water & Farming (TURV)Two Rivers Water & Farming (OTCMKTS:TURV) acquires and develops farmland and associated water rights. It provides greenhouses and processing facilities for marijuana growers in Colorado with water rights not used for fruit and vegetable production.TURV got my attention because the stock has been mostly trending higher since March. Maybe it is doing well because this company is different than most other penny stock companies. Two Rivers actually makes money. Last earnings report, it revealed earnings of 9 cents per share. * 10 Best Stocks for 2019: A Volatile First Half There has also been some recent positive news. The company just announced a new pilot project to manage hemp production on a large farm in Colorado. Management believes that this will pave the way for further expansion. National Access Cannabis Corp (NACNF)National Access Cannabis Corp (OTCMKTS:NACNF) is a recreational cannabis retailer in Canada.This retailer may be in a great position to profit from the enormous growth of the cannabis industry. A frequently mentioned report by Arcview Market Research and BDS Analytics states consumer spending on cannabis may increase by almost 40% this year.National Access currently operates 23 stores in Canada. Since cannabis became legal in October the company has had about $27 CAD million of sales with impressive gross margins that are around 31%.By the end of the year, the company plans to have 40 stores opened and operating. With this rate of anticipated growth, this company may have great future potential. Pivot Pharmaceuticals Inc (PVOTF)Pivot Pharmaceuticals Inc (OTCMKTS:PVOTF) is an early stage pharmaceutical company that engages in the development and commercialization of therapeutic and nutraceutical products.PVOTF has been acting well since April. This may be due to the fact the company just hired an experienced chief operating officer to strengthen its management team.The cannabis industry is full of incompetent management. Many entrepreneurs may have great ideas and can get a company up and running, but they do not have the skills to manage the company as it grows and matures. Pivot's recognition of the need for experienced people could be a good sign. * 7 A-Rated Stocks to Buy for the Rest of 2019 It also announced that it is expanding its Board of Directors. This move could attract investors. Some investors think the composition of the Board is extremely important and analyze it as part of their investment research process. Cannabics Pharmaceuticals Inc (CNBX)Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is an early stage biotechnology company that develops personalized anti-cancer and palliative treatments.There is a very cool story here. This company is trying to develop medicinal marijuana that will treat and potentially cure cancer. But CNBX stock got my attention because it is trading at a level that has been support in the past. After finding support at these levels in December, the stock more than doubled.An important thing to consider here is that in its most recent quarter, CNBX stock reported earnings of 3 cents per share. That doesn't sound too impressive at first glance, but when you consider that most of these other penny-stock marijuana companies are losing money, you can understand the significance.Now that CNBX stock is on my radar screen, I will be watching it to see if this support holds over the next month or two. If so, I will do some more research. Earth Science Tech Inc. (ETST)Earth Science Tech Inc. (OTCMKTS:ETST) researches and develops cannabis and industrial hemp.This company holds a portfolio of diverse subsidiaries. In early June, the stock dipped to lows around 30 cents. Since then, the stock has rallied.This company caught my attention due to the extensive experience of the management team and advisory board. As I said before, many of these little marijuana companies are run by inexperienced people. ETST stock appears to be different. * 7 Retail Stocks to Buy for the Second Half of 2019 Chief Financial Officer Wendell Hecker has more than 30 years of experience in large New York City based corporations. The chief operations officer and the chief sales officer are also veterans. They each have more than two decades of experience. To see insiders with this amount of experience is unusual in this industry. Halo Labs (AGEEF)Halo Labs (OTCMKTS:AGEEF) develops and manufactures cannabis oils and concentrates.This company caught my attention because despite some volatility, it has trended higher since the beginning of the year. In January it was trading around 22 cents and the most recent close was 42 cents.There have been some developments at Halo that seem to be positive. This is what could be driving this move.Last month, the company reported that its revenues had tripled to almost $9 million. This was attributed to the launching of cannabis oil and concentrate operations in Canada and Nevada.In addition to this, AGEEF stock started trading on the OTCQX. This is one of the tiers or levels of the Canadian OTC Market. Before this, it traded on a lower tier.Because the higher tier requires more transparency and disclosure, some investors may consider this to be a positive development for the long-term prospects of the company.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on College Students' Radars * 7 Retail Stocks to Buy for the Second Half of 2019 * The S&P 500's 5 Best Highest-Yielding Dividend Stocks The post 7 Marijuana Penny Stocks That I May Buy appeared first on InvestorPlace.

Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

HOD HASHARON, Israel, June 28, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (CNBX) have together created and adopted a business plan for their joint venture (JV), a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the JV was a condition for the planned venture to move forward. Having assessed the regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings, we are eagerly engaging in technology development and clinical advancement.

/C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph, 1st sentence, should read "Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel." rather than as originally issued inadvertently. TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. "This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada," stated Mr. Barad.

Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California. Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President at LD Micro.